and was the first anti-cancer Danoprevir ITMN-191 compound, which are in a phase of 0 degree in patients evaluated in the treatment of advanced tumors. ABT 888 has provided good oral bioavailability, with a half-life of several hours to the test and the blood-brain barrier. PARP activity Was pharmacodynamic t according to the levels of RAP validated by ELISA and IHC to determine the pharmacokinetic profile of ABT 888th Treatment with ABT 888 has entered Born in a significant decrease in levels of PAR and erh Hen the level of expression of PARP1. A clinical trial is underway to identify which patients by measuring the formation of foci of FANCD2 and H2AX in tumors treated with ABT alone or FFPE 888. In combination with chemotherapy Undergo a series of phase II trials I clinical that ABT 888 as monotherapy or in combination with chemotherapeutic agents, including normal carboplatin, paclitaxel, cisplatin, temozolomide, topotecan, cyclophosphamide, recurrent or metastatic breast cancer and epithelial ovarian cancer, colon cancer and glioblastoma.
Iniparib developed by Bi, and now Sanofi Aventis, was the first PARP inhibitor currently in Phase III clinical trials of breast and non-small lung cancer type. Iniparib is a potent inhibitor of PARP1 and erm other enzymes Glicht LY294002 by an irreversible, covalent modification. This inhibitor other a different mechanism of action of PARP inhibitors, because it forms a covalent bond. Iniparib, either alone or in combination with chemotherapy, have significant anti-tumor activity t in pr Clinical studies in vitro and in vivo. Iniparib is evaluated in several phase II and phase III clinical trials for breast, ovarian, Geb Rmutter and brain tumors. The Phase III trial was started in July 2009, is a multicenter, randomized trial evaluating the safety and efficacy of iniparib review when.
With gemcitabine and carboplatin as first, second and third combined in women with metastatic triple-negative Another randomized phase III trial of gemcitabine with or without carboplatin in patients with epidermal iniparib cancer With previously untreated advanced lung cancer cell is in progress. Preferences INDICATIVE data on TNBC are promising phase I clinical trials in patients with solid tumors have shown that treatment with iniparib with minimal toxicity T was associated. A randomized phase II study of Sanofi Aventis were reported 71.7 of 120 patients with metastatic triple-negative receive iniparib in combination with gemcitabine and carboplatin showed a clinical benefit. Combination of iniparib to gemcitabine and carboplatin has also improved tumor response, progression-free survival and overall survival in this cohort of patients. Phase I and II studies iniparib in combination with temozolomide in the treatment of patients with newly diagnosed malignant glioma is ongoing. Several clinical phase II iniparib as monotherapy or in combination with chemotherapy with cisplatin gemcitabine and carboplatin in other tumor types, current success